BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol. 2019;70:839-846. [PMID: 30654067 DOI: 10.1016/j.jhep.2019.01.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Curtis M, Higgs P, Stoové M. Prison-based harm reduction measures as part of hepatitis C virus treatment. The Lancet Gastroenterology & Hepatology 2019;4:903. [DOI: 10.1016/s2468-1253(19)30335-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Draper B, Yee WL, Pedrana A, Kyi KP, Qureshi H, Htay H, Naing W, Thompson AJ, Hellard M, Howell J. Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients. Lancet Reg Health West Pac 2022;20:100359. [PMID: 35024676 DOI: 10.1016/j.lanwpc.2021.100359] [Reference Citation Analysis]
3 Corcorran MA, Ludwig-Baron N, Cheng DM, Lioznov D, Gnatienko N, Patts G, So-Armah K, Blokhina E, Bendiks S, Krupitsky E, Samet JH, Tsui JI. The Hepatitis C Continuum of Care Among HIV-Positive Persons with Heavy Alcohol Use in St. Petersburg, Russia. AIDS Behav 2021;25:2533-41. [PMID: 33730255 DOI: 10.1007/s10461-021-03214-y] [Reference Citation Analysis]
4 Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy 2020;86:102964. [DOI: 10.1016/j.drugpo.2020.102964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
6 Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021. [PMID: 34339561 DOI: 10.1111/jvh.13586] [Reference Citation Analysis]
7 Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lazarus JV, Picchio CA, Guy D, Aleman S, James C, Nava FA, Øvrehus A, Turnes J, Ward JW, Ustianowski A. Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. Clin Res Hepatol Gastroenterol 2021;45:101564. [PMID: 33740477 DOI: 10.1016/j.clinre.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Price JC, Simpson DC. Telemedicine and Health Disparities. Clinical Liver Disease. [DOI: 10.1002/cld.1171] [Reference Citation Analysis]
10 Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. BMC Public Health 2020;20:1670. [PMID: 33167912 DOI: 10.1186/s12889-020-09515-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hariri S, Alavi M, Roshandel G, Mohammadi Z, Fazel A, Amiriani T, Bazazan A, Motamed-Gorji N, Sohrabpour A, Merat S, Poustchi H, Malekzadeh R. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Int J Drug Policy 2021;95:103269. [PMID: 33991887 DOI: 10.1016/j.drugpo.2021.103269] [Reference Citation Analysis]
12 Halder A, Li VG, Sebastian M, Nazareth S, Tuma R, Cheng W, Doyle A. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C. Intern Med J 2021;51:1344-7. [PMID: 34423535 DOI: 10.1111/imj.15451] [Reference Citation Analysis]
13 Giuliani R, Casigliani V, Fornili M, Sebastiani T, Freo E, Arzilli G, Scardina G, Baglietto L, Tavoschi L, Ranieri R. HCV micro-elimination in two prisons in Milan, Italy: A model of care. J Viral Hepat 2020;27:1444-54. [PMID: 32815623 DOI: 10.1111/jvh.13376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
15 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Brixko C, Laukens P, Orlent H, Bilaey P, De Smet F, Hellemans G, Muyldermans G, Van Baelen L, Hens N, Van Vlierberghe H, Robaeys G. A multicentre interventional study to assess blood-borne viral infections in Belgian prisons. BMC Infect Dis 2021;21:708. [PMID: 34315415 DOI: 10.1186/s12879-021-06405-z] [Reference Citation Analysis]
16 Tavoschi L. Treatment-as-prevention in prison settings: a growing evidence base for HCV elimination efforts. Lancet Gastroenterol Hepatol 2021;6:512-3. [PMID: 33965005 DOI: 10.1016/S2468-1253(21)00133-3] [Reference Citation Analysis]
17 Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
18 Abdelwadoud M, Mattingly TJ 2nd, Seguí HA, Gorman EF, Perfetto EM. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. Patient 2021;14:471-84. [PMID: 33372245 DOI: 10.1007/s40271-020-00489-6] [Reference Citation Analysis]
19 Rodrigues B, Parsons N, Haridy J, Bloom S, Day C, Haar G, Nicoll A, Sawhney R. A nurse-led, telehealth-driven hepatitis C management initiative in regional Victoria: Cascade of care from referral to cure. J Telemed Telecare 2021;:1357633X211024108. [PMID: 34142898 DOI: 10.1177/1357633X211024108] [Reference Citation Analysis]
20 Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada. Int J Drug Policy 2021;88:102738. [PMID: 32278651 DOI: 10.1016/j.drugpo.2020.102738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
21 Gallacher J, McPherson S. Progress towards micro-elimination of hepatitis C in the custodial setting. J Viral Hepat 2021;28:300-1. [PMID: 33131191 DOI: 10.1111/jvh.13428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
23 Ramachandran J, Kaambwa B, Muller K, Haridy J, Tse E, Tilley E, Altus R, Waddell V, Gordon D, Shaw D, Huynh D, Stewart J, Nelson R, Warner M, Boyd MA, Chinnaratha MA, Harding D, Ralton L, Colman A, Woodman R, Wigg AJ. Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience. Eur J Gastroenterol Hepatol 2020;32:1381-9. [PMID: 31895911 DOI: 10.1097/MEG.0000000000001659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson AJ. Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. PLoS One 2020;15:e0242101. [PMID: 33206696 DOI: 10.1371/journal.pone.0242101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Gagné M, Têtu I, Grégoire J, Moisan J. Adherence and sustained virologic response among vulnerable people initiating an hepatitis C treatment at a nurse-led clinic: A non-experimental prospective cohort study based on clinical records. International Journal of Nursing Studies Advances 2021;3:100029. [DOI: 10.1016/j.ijnsa.2021.100029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fiore V, De Matteis G, Ranieri R, Saderi L, Pontali E, Muredda A, Ialungo AM, Caruso R, Madeddu G, Sotgiu G, Babudieri S. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy. 2021;90:103055. [PMID: 33310637 DOI: 10.1016/j.drugpo.2020.103055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
27 Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users–Prisons Network. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol 2021;6:391-400. [PMID: 33857445 DOI: 10.1016/S2468-1253(20)30365-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Reference Citation Analysis]
29 Piao C, Terrault NA, Sarkar S. Telemedicine: An Evolving Field in Hepatology. Hepatol Commun. 2019;3:716-721. [PMID: 31061958 DOI: 10.1002/hep4.1340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
30 Overton K, Clegg J, Pekin F, Wood J, Mcgrath C, Lloyd A, Post JJ. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. International Journal of Drug Policy 2019;72:123-8. [DOI: 10.1016/j.drugpo.2019.02.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
31 Kronfli N, Dussault C, Bartlett S, Fuchs D, Kaita K, Harland K, Martin B, Whitten-nagle C, Cox J. Disparities in hepatitis C care across Canadian provincial prisons: Implications for hepatitis C micro-elimination. CanLivJ 2021;4:292-310. [DOI: 10.3138/canlivj-2020-0035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
33 Mohamed Z, Al-Kurdi D, Nelson M, Shimakawa Y, Selvapatt N, Lacey J, Thursz MR, Lemoine M, Brown AS. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. Int J Drug Policy 2020;75:102608. [PMID: 31759307 DOI: 10.1016/j.drugpo.2019.102608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
34 Stewart AC, Cossar RD, Wilkinson AL, Quinn B, Dietze P, Walker S, Butler T, Curtis M, Aitken C, Kirwan A, Winter R, Ogloff J, Kinner S, Stoové M. The Prison and Transition Health (PATH) cohort study: Prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria, Australia. Drug Alcohol Depend 2021;227:108970. [PMID: 34488074 DOI: 10.1016/j.drugalcdep.2021.108970] [Reference Citation Analysis]
35 Kamarulzaman A, Verster A, Altice FL. Prisons: ignore them at our peril. Curr Opin HIV AIDS 2019;14:415-22. [PMID: 31343458 DOI: 10.1097/COH.0000000000000572] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
37 Chan J, Kaba F, Schwartz J, Bocour A, Akiyama MJ, Rosner Z, Winters A, Yang P, MacDonald R. The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017. EClinicalMedicine 2020;27:100567. [PMID: 33150329 DOI: 10.1016/j.eclinm.2020.100567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Fung BM, Perumpail M, Patel YA, Tabibian JH. Telemedicine in Hepatology: Current Applications and Future Directions. Liver Transpl 2021. [PMID: 34506686 DOI: 10.1002/lt.26293] [Reference Citation Analysis]
39 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
40 Kozlowski HN, Sindhwani S, Chan WCW. The Impact of Patient Characteristics on Diagnostic Test Performance. Small Methods 2022;:e2101233. [PMID: 34994108 DOI: 10.1002/smtd.202101233] [Reference Citation Analysis]
41 Wang CW, Chuang HY, Chiang HC, Huang PC, Yu ML, Dai CY. Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy. J Chin Med Assoc 2020;83:454-60. [PMID: 32358454 DOI: 10.1097/JCMA.0000000000000312] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Richmond JA, Gallagher L, McDonald L, O'Sullivan M, Fitzsimmons C, Pedrana A. Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies. Gastroenterol Nurs 2020;43:303-9. [PMID: 32665524 DOI: 10.1097/SGA.0000000000000458] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Palmer A, Papaluca T, Stoové M, Winter R, Pedrana A, Hellard M, Wilson D, Thompson A, Scott N; EC Victoria Partnership. A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison. Int J Drug Policy 2021;94:103203. [PMID: 33744667 DOI: 10.1016/j.drugpo.2021.103203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. Clin Mol Hepatol 2021;27:474-85. [PMID: 33601868 DOI: 10.3350/cmh.2021.0015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Bartlett SR, Buxton J, Palayew A, Picchio CA, Janjua NZ, Kronfli N. Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era. Clin Liver Dis (Hoboken) 2021;17:75-80. [PMID: 33680440 DOI: 10.1002/cld.1023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]